Transcriptomic Analysis of Peripheral Monocytes upon Fingolimod Treatment in Relapsing Remitting Multiple Sclerosis Patients.
G SferruzzaF ClarelliE MasciaL FerrèL OttoboniM SorosinaS SantoroL MoiolaV MartinelliG ComiF Martinelli BoneschiM FilippiP ProveroFederica EspositoPublished in: Molecular neurobiology (2021)
Fingolimod (FTY), a second-line oral drug approved for relapsing remitting Multiple Sclerosis (RRMS) acts in preventing lymphocyte migration outside lymph nodes; moreover, several lines of evidence suggest that it also inhibits myeloid cell activation. In this study, we investigated the transcriptional changes induced by FTY in monocytes in order to better elucidate its mechanism of action. CD14+ monocytes were collected from 24 RRMS patients sampled at baseline and after 6 months of treatment and RNA profiles were obtained through next-generation sequencing. We conducted pathway and sub-paths analysis, followed by centrality analysis of cell-specific interactomes on differentially expressed genes (DEGs). We investigated also the predictive role of baseline monocyte transcription profile in influencing the response to FTY therapy. We observed a marked down-regulation effect (60 down-regulated vs. 0 up-regulated genes). Most of the down-regulated DEGs resulted related with monocyte activation and migration like IL7R, CCR7 and the Wnt signaling mediators LEF1 and TCF7. The involvement of Wnt signaling was also confirmed by subpaths analyses. Furthermore, pathway and network analyses showed an involvement of processes related to immune function and cell migration. Baseline transcriptional profile of the HLA class II gene HLA-DQA1 and HLA-DPA1 were associated with evidence of disease activity after 2 years of treatment. Our data support the evidence that FTY induces major transcriptional changes in monocytes, mainly regarding genes involved in cell trafficking and immune cell activation. The baseline transcriptional levels of genes associated with antigen presenting function were associated with disease activity after 2 years of FTY treatment.
Keyphrases
- multiple sclerosis
- disease activity
- systemic lupus erythematosus
- transcription factor
- dendritic cells
- rheumatoid arthritis
- end stage renal disease
- peripheral blood
- rheumatoid arthritis patients
- genome wide
- lymph node
- ejection fraction
- acute myeloid leukemia
- white matter
- cell migration
- chronic kidney disease
- machine learning
- peritoneal dialysis
- immune response
- newly diagnosed
- emergency department
- juvenile idiopathic arthritis
- prognostic factors
- copy number
- replacement therapy
- mass spectrometry
- combination therapy
- dna methylation
- heat shock protein
- case report